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ORIGINAL ARTICLE

Methylation of the leukocyte glucocorticoid receptor gene
promoter in adults: associations with early adversity and
depressive, anxiety and substance-use disorders
AR Tyrka1,2, SH Parade2,3, ES Welch1, KK Ridout1,2, LH Price1,2, C Marsit4,5, NS Philip1,2,6 and LL Carpenter1,2
Early adversity increases risk for developing psychopathology. Epigenetic modiﬁcation of stress reactivity genes is a likely
mechanism contributing to this risk. The glucocorticoid receptor (GR) gene is of particular interest because of the regulatory role
of the GR in hypothalamic–pituitary–adrenal (HPA) axis function. Mounting evidence suggests that early adversity is associated
with GR promoter methylation and gene expression. Few studies have examined links between GR promoter methylation and
psychopathology, and ﬁndings to date have been mixed. Healthy adult participants (N = 340) who were free of psychotropic
medications reported on their childhood experiences of maltreatment and parental death and desertion. Lifetime depressive and
anxiety disorders and past substance-use disorders were assessed using the Structured Clinical Interview for the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition. Methylation of exon 1F of the GR gene (NR3C1) was examined in leukocyte
DNA via pyrosequencing. On a separate day, a subset of the participants (n = 231) completed the dexamethasone/corticotropinreleasing hormone (Dex/CRH) test. Childhood adversity and a history of past substance-use disorder and current or past depressive
or anxiety disorders were associated with lower levels of NR3C1 promoter methylation across the region as a whole and at
individual CpG sites (P o 0.05). The number of adversities was negatively associated with NR3C1 methylation in participants with no
lifetime disorder (P = 0.018), but not in those with a lifetime disorder. GR promoter methylation was linked to altered cortisol
responses to the Dex/CRH test (P o 0.05). This study presents evidence of reduced methylation of NR3C1 in association with
childhood maltreatment and depressive, anxiety and substance-use disorders in adults. This ﬁnding stands in contrast to our prior
work, but is consistent with emerging ﬁndings, suggesting complexity in the regulation of this gene.
Translational Psychiatry (2016) 6, e848; doi:10.1038/tp.2016.112; published online 5 July 2016

INTRODUCTION
Substantial evidence from animal models and human studies
implicates impairments in glucocorticoid signaling in stressrelated psychiatric disorders, such as major depressive disorder
(MDD) and post-traumatic stress disorder (PTSD). Changes in
glucocorticoid receptor (GR) number and function in the brain and
in peripheral cells such as leukocytes have been shown with PTSD,
MDD and early stress exposure,1–8 and alterations of diurnal and
reactive cortisol concentrations are seen in adults and children
with these conditions.9–11 GR-mediated negative feedback has a
critical role in dampening activity of the hypothalamic–pituitary–
adrenal (HPA) axis so that changes in GR number or function can
inﬂuence activity of this system and, consequently, the biological
adaptation to stressful or traumatic experiences. Because childhood maltreatment and other adverse experiences are major risk
factors for the development of psychopathology, including
depressive, anxiety and substance-use disorders,12–15 stressinduced alterations in glucocorticoid signaling may be a mechanism of these associations.
Expression of the human GR gene, NR3C1, is regulated by
a variety of transcriptional and translational mechanisms.16

A growing area of research is aimed at determining whether
early-life stress is associated with epigenetic changes to the
promoter region of NR3C1 that alter GR expression and potentially
alter HPA-axis homeostasis and responses to stress. Epigenetic
modiﬁcations to the genome allow for altered gene expression
but do not change the DNA sequence and thus permit elaboration
of the genome beyond what is determined by DNA base
coding.17,18 Methylation, involving the addition of a methyl group
to DNA, is thought to be the most stable form of epigenetic
alteration.18,19 Typically, this occurs at sites where a cytosine
nucleotide occurs next to a guanine nucleotide (CpG dinucleotides), although non-CpG methylation has been discovered in
embryonic stem cells and in some adult brain, skeletal muscle, and
hematopoietic cells.20 Methylation at promoter CpG sites can lead
to alterations in chromatin architecture and inhibit transcription
factor (TF) binding, often resulting in reduced gene expression.
Consistent with this, genes such as NR3C1 that are highly expressed
typically have low levels of promoter methylation.17,21,22
Differential methylation has been shown to be associated with
stress exposure early in life. Early studies in rodents with naturally
occurring differences in maternal care showed that low levels of
care were associated with greater methylation of the GR gene,
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speciﬁcally in the promoter region homologous to the human
exon 1F.23,24 The epigenetic effects of differential maternal care
were associated with long-lasting effects on stress responses.23,24
Subsequently, a number of studies in humans across the
developmental spectrum have documented a relationship
between early environmental exposures and increased methylation of the alternate ﬁrst exons in the NR3C1 promoter.25,26
Beginning with prenatal exposure, several studies have
demonstrated that exposure to maternal depression, anxiety or
trauma during gestation is associated with greater levels of
methylation of the 1F region in DNA from placental tissue and
umbilical cord blood.27–31 Childhood maltreatment was associated
with increased NR3C1 methylation in leukocyte DNA from children
aged 11–14 years32 and in saliva DNA from preschool-aged
children.33 Two studies of adolescents have also shown positive
associations of methylation of the NR3C1 promoter in peripheral
blood DNA with prenatal exposure to intimate partner violence34
or traumatic experiences in childhood.35 The enduring effects
of early stress are appreciated from evidence that alterations of
NR3C1 promoter methylation were seen in adults with a history of
childhood adversity. In a preliminary study of healthy adults with
no lifetime psychopathology, our group found positive associations of 1F methylation with childhood parental loss and
maltreatment that were not accounted for by recent perceived
stress.36 Taken together, these ﬁndings suggest that altered NR3C1
methylation is linked to early stress exposure, and thus might
predispose to the development of psychopathology.
Early-life adversity is a known risk factor for psychopathology
later in life,12–15 and differential methylation of genes important to
the regulation of stress, such as the GR, may be a mechanism of
this effect. However, few studies have examined the relationship
between NR3C1 methylation, childhood adversity and psychopathology. We recently reported that methylation of saliva DNA
NR3C1 in association with maltreatment and other adversities in
maltreated preschool-aged children mediated the link between
early stress exposure and internalizing behaviors (that is, withdrawn, somatic, anxious and depressed).37 In a study of postmortem brain from suicides, subjects with a history of childhood
abuse had differential NR3C1 promoter methylation compared
with suicide completers without a history of childhood abuse and
controls without a history of childhood abuse or suicide.38 Several
investigations found altered methylation of sites in the NR3C1
promoter region in those with psychopathology.39–46 A few
studies have examined effects of childhood adversity within the
sample as a whole, with some ﬁnding no effect39,43–45 and others
ﬁnding an effect of early-life stress on increased NR3C1
methylation.41,47,48 However, these have not speciﬁcally examined
the differential contributions of early stress and psychopathology
to NR3C1 methylation. Moreover, most prior work in individuals
with psychiatric disorders included participants on psychotropic
medication, which can alter methylation levels.48–50
Another issue requiring further study is the direction of
methylation effects in association with early stress and psychopathology. For early stress, most work has identiﬁed hypermethylation of NR3C1 in the 1F region or its rat homolog.25 However, a
number of these studies reported lower levels of methylation in
some of the 1F CpG sites,28,32,35,38 and examination of methylation
at speciﬁc CpG sites may be important to understand the
regulation of this gene.51,52 For psychopathology, ﬁndings as to
the direction of methylation effects have been mixed. Increased
levels of NR3C1 promoter methylation have been shown among
children and adolescents with depression or internalizing
problems;46,53 however, a study of depressed outpatients documented decreased levels of methylation in comparison with
controls.42 Increased methylation has been documented in
borderline personality disorder39,41 and in women with comorbid
borderline personality disorder and bulimia nervosa.43 In contrast,
several studies have demonstrated lower levels of NR3C1
Translational Psychiatry (2016), 1 – 9

methylation in patients with PTSD as compared with healthy
controls45,54 and PTSD symptoms in men.44 Finally, recent
research has shown that externalizing disorders and problems
are also characterized by hypomethylation of NR3C1.40,55
In order to examine these issues, the present study investigated
methylation of the NR3C1 1F promoter region in adults with and
without a history of childhood adversity, and with and without a
lifetime psychiatric diagnosis of depressive, anxiety or substanceuse disorder.
MATERIALS AND METHODS
Participants
Three-hundred and forty adults, 213 women and 127 men, aged 18–65
(32.9 ± 11.5) years, were recruited in a series of related studies using
separate local, newspaper and internet advertisements directed toward
healthy adults, adults with depression, individuals with a history of early
parental loss and adults with a history of early-life stress. This sample did
not include the participants from our prior study of childhood adversity
and NR3C1 methylation.36 The study was approved by the Butler Hospital
Institutional Review Board, and, after complete description of the study to
the participants, voluntary written informed consent was obtained.
Exclusions included prescription medication use other than oral
contraceptives, reported acute or chronic medical illness, pregnancy, a
history of brain injury or seizure disorder, night-shift work and current
alcohol- or substance-use disorders because of possible effects on activity
of the HPA axis. In addition, excluded were those with a lifetime history of
bipolar disorder, psychotic disorder and obsessive–compulsive disorder.
The subset of participants who completed the dexamethasone/corticotropin-releasing hormone (Dex/CRH) test (n = 231) completed a physical
examination, electrocardiogram and standard laboratory studies to further
rule out acute or unstable medical illness. Oral contraceptives were
allowed, with usage accounted for in analyses of cortisol concentrations.

Assessment of diagnoses and symptoms
Axis I psychiatric diagnoses were assessed using the Structured Clinical
Interview for the Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition.56 The 30-item Inventory of Depressive Symptomatology,
Self-Report version,57 the State-Trait Anxiety Inventory58 and the Perceived
Stress Scale59 were included to assess symptoms of depression and anxiety
and recent perceived stress.

Childhood adversity
Participant interview was used to elicit the history of loss of a parent before
the age of 18 (N = 88). This category included death (n = 38) of a parent and/or
prolonged separation/desertion (that is, parent deserted for at least 6 months
with no attempts at contact or responses to child’s attempts, n = 51).
The 28-item Childhood Trauma Questionnaire60 is a self-report measure
that generates a total score summarizing ﬁve types of childhood
maltreatment (physical, sexual and emotional abuse, physical and
emotional neglect), with high internal consistency, test–retest reliability
and convergent validity.60–65 Threshold scores corresponding with
'moderate' or 'severe' exposure on each maltreatment subscale were used
to deﬁne the presence of each adversity type on this scale.63 Adversity was
considered present if the score was greater than or equal to 13 for
emotional abuse, 10 for physical abuse, 8 for sexual abuse, 10 for physical
neglect and 15 for emotional neglect.
Participants who experienced parental death or desertion or at least one
of the maltreatment types assessed by the Childhood Trauma Questionnaire were considered to have experienced childhood adversity. In
addition, an index of early stress exposure was created by summing the
number of adversities (parental death, parental desertion and the ﬁve
types of childhood maltreatment on the Childhood Trauma Questionnaire).

NR3C1 promoter methylation sequencing
Whole blood was frozen within 20 min of blood draw at − 80 °C until
processing. Samples were labeled with a numerical code only, and
laboratory personnel were blind to subject characteristics. DNA was
extracted from frozen whole blood using PAXgene reagents (Qiagen,
Valencia, CA, USA) according to the manufacturer’s directions. Methylation
at the NR3C1 promoter region was examined with a quantitative
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pyrosequencing approach following the method of Oberlander and
colleagues as previously described.31,36 The region analyzed contains 13
CpGs and encompasses exon 1F, the human homolog of the rat exon 17.
Sodium bisulﬁte modiﬁcation of 500 ng of DNA was performed using the
EZ DNA Methylation Kit (Zymo Research, Orange, CA, USA) following the
manufacturer’s protocol. For quality control, PCR products were visualized
and sized on an agarose gel (FlashGel, Lonza, Basel, Switzerland); samples
were run in triplicate for pyrosequencing and data points were rejected if
they were greater or less than two times the s.d. of the mean of the
triplicate group. Peripheral blood lymphocyte DNA that was not sodium
bisulﬁte-modiﬁed was included in each pyrosequencing run and served as
a control for nonspeciﬁc ampliﬁcation. Methylation quantiﬁcation was
performed using the Pyromark Software (Qiagen). The percent of alleles
that were methylated in the cell population examined was used in
statistical analyses.

Dex/CRH test
On a subsequent visit, 231 of the participants completed the Dex/CRH test.
The night before the test, an oral dose of dexamethasone 1.5 mg was selfadministered at 2300 hours. The following day, participants arrived at
1200 hours and were given lunch. A topical anesthetic (lidocaine 2.5% and
prilocaine 2.5%) was applied to the participant’s forearm between 1230
and 1245 hours. At 1300 hours an indwelling intravenous catheter was
inserted in the forearm by a highly experienced research nurse.
Participants then remained in a semi-recumbent position throughout the
procedure except to use the bathroom. They were permitted to read or
watch pre-selected materials that did not contain emotionally charged
material. Vital signs were monitored throughout the test. At 1500 hours,
CRH 100 μg (corticorelin ovine triﬂutate, Acthrel, Ferring Pharmaceuticals,
Parsippany, NJ, USA) reconstituted in 2 ml of 0.9% NaCl solution was
infused intravenously over 30 s. Blood samples were drawn at 1459, 1530,
1545, 1600, 1615 and 1700 hours and assayed for cortisol. The 1459 hours
sample represents the response to dexamethasone (post-Dex) before
administration of CRH infusion.

Hormone assays
Plasma cortisol concentrations were assayed in duplicate using the
following assays and following the manufacturers’ instructions. Samples
were labeled with a numerical code only and laboratory personnel were
blind to subject characteristics. The Gamma Coat cortisol I-125 coated-tube
radioimmunoassay kit (INCSTAR, Stillwater, MN, USA) was used for 106
participants. Intra- and interassay CVs observed for quality assessment
samples (5 and 20 μg /dl) were less than 5% and 10%, respectively. The
double antibody DSL-2000 Cortisol Radioimmunoassay Kit (Diagnostic
Systems Laboratories, Webster, TX, USA) was used for 81 participants. The
intra- and interassay coefﬁcients of variation are 5.3% and 7.0%,
respectively. The cortisol Chemiluminescence Immunoassay kit (Beckman-Coulter, Brea, CA, USA) was used for 44 participants. The intra- and
interassay coefﬁcients of variation are both 4.3%. Variation between these
three assay types was assessed in n = 19 samples that were analyzed using
more than one assay type, and results showed very high correlations
(r = 0.92–0.98). Area under the curve (AUC) over time for cortisol response
to the Dex/CRH test was calculated using the trapezoidal rule. Post-Dex
and AUC values were log-transformed because of positive skew.

Statistical analysis
In order to test hypothesized effects of early stress and psychopathology,
four groups were examined: participants with no early adversity and no
lifetime psychiatric diagnosis (n = 96, No Adversity/No Disorder group),
participants with early adversity but no lifetime diagnosis (n = 60,
Adversity/No Disorder group), participants with a lifetime diagnosis but
no history of early adversity (n = 51, No Adversity/Disorder group) and
those with both early adversity and a lifetime diagnosis (n = 133, Adversity/
Disorder group). Subsequent analyses examined effects of speciﬁc disorder
categories (lifetime MDD, lifetime depressive disorder (including MDD),
lifetime PTSD, lifetime anxiety disorder (including PTSD) and past
substance-use disorder) and childhood adversity types (physical abuse,
sexual abuse, emotional abuse, physical neglect, emotional neglect,
parental death and parental desertion). Effects of the number of adversities
on methylation were also examined.
Our primary analyses examined effects of the adversity/disorder
grouping on mean percent methylation of CpG sites across the 1F region.
Methylation was correlated across CpG sites in this region. As with our

prior work, CpG 7–13 were most highly intercorrelated (r = 0.72-0.91) and
CpG 1–6 were more modestly intercorrelated (r = 0.42–0.66). Correlations
across CpG 1–6 and CpG 7–13 were r = 0.33–0.78. Given this intercorrelation, we examined mean methylation across the entire region, and, in the
case of a signiﬁcant overall effect on mean methylation, we then
conducted follow-up analyses to examine individual CpG sites. We did
not adjust for multiple comparisons because individual sites were only
examined as post hoc comparisons in the event of a signiﬁcant omnibus
test. Outliers, deﬁned as values more than three s.d.'s from the mean, were
Winsorized by setting them to the next highest value within three s.d.'s.
The number of outliers at each individual CpG site ranged from 1 (CpG 5)
to 9 (CpG 1), with a mean of 5.4 outliers at each site (1.6% of the sample).
Analyses were conducted with SPSS version 20 (IBM, Armonk, NY, USA).
All analyses were two-tailed with alpha = 0.05 and data conformed to the
assumptions of the statistical tests. Levene's test of the homogeneity of
variance demonstrated that for mean methylation across the 13 CpG sites,
the variances were equal across the four Adversity/Disorder groups (F(3,
336) = 1.27, P = 0.286). With N = 340, we have power ≥ 0.80 to detect effect
sizes as small as f = 0.18, a small-medium-sized effect.66 Demographic
characteristics, as well as recent perceived stress levels and subsyndromal
symptoms of depression and anxiety, were examined and controlled
where appropriate. General linear models, controlling for relevant
covariates, were used to test for effects of adversity and psychopathology.
Partial correlations, controlling for age, sex and oral contraceptive use,
were used to examine associations of NR3C1 methylation with post-Dex
and AUC cortisol in the Dex/CRH test. Error bars in ﬁgures represent s.e.m.

RESULTS
Preliminary analyses
Participant characteristics are displayed in Table 1. One hundred
and ninety-three participants reported a history of early adversity;
184 had a past substance-use disorder or a current or lifetime
depressive or anxiety disorder (see table for types of adversity and
disorders). Participants in the Adversity/Disorder group were
signiﬁcantly older than those in the other groups (Table 1), and
age was associated with methylation at CpG 1 (r = 0.13, P = 0.020)
and CpG 2 (r = 0.13, P = 0.014). Gender did not differ according to
group; however, women had greater methylation at CpG 3 than
men (t = − 2.01, P = 0.046). To control for these associations, age
and gender were included as covariates in models testing
associations of the Adversity/Disorder groupings and NR3C1
methylation. The Adversity/Disorder groups differed with respect
to the proportion of participants who identiﬁed their race as white
versus those who identiﬁed another race (Table 1). However, there
were no differences in NR3C1 methylation at any of the CpG sites
based on race, and associations of the Adversity/Disorder groupings and the number of adversities with NR3C1 did not differ when
race was included in the models; therefore, it was not further
considered. There was no difference in mean methylation across
the 13 CpG sites between women with and without use of oral
contraceptives. For analyses testing associations of the Adversity/
Disorder grouping and the Dex/CRH test response, use of oral
contraceptives was associated with greater post-dexamethasone
cortisol (t = − 6.19, P o 0.001) and greater cortisol at 120 min
following CRH administration (t = − 2.03, P = 0.043); this variable
was controlled in addition to age and gender.
Associations of Adversity/Disorder grouping variable with NR3C1
methylation
The Adversity/Disorder grouping variable was associated with
mean methylation across the 13 CpG sites (F(3, 334) = 3.68,
P = 0.012). The No Adversity/No Disorder group had signiﬁcantly
higher levels of mean methylation than the Adversity/No Disorder
group (P = 0.013) and the Adversity/Disorder group (P = 0.002), and
this difference was at the trend level for the No Adversity/Disorder
group (P = 0.06). Post hoc examination of individual CpG sites
(Figure 1) revealed that there were signiﬁcant differences between
the four groups at CpG 6 (F = 6.65, P o 0.001), CpG 9 (F = 6.28,
Translational Psychiatry (2016), 1 – 9
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Table 1.

Adversity/Disorder grouping variable descriptives

Age M (s.d.)
Sex N (%) male
Race N (%) white
Education N (%), ≥ college degree
Emotional abuse N (%)
Physical abuse N (%)
Sexual abuse N (%)
Emotional neglect N (%)
Physical neglect N (%)
Parental death N (%)
Parental desertion N (%)
Number of adversities M (s.d.)
Current MDD N (%)
Past MDD N (%)
Current dysthymia/Dep NOS N (%)
Past dysthymia/Dep NOS N (%)
Current PTSD N (%)
Past PTSD N (%)
Current social phobia N (%)
Past social phobia N (%)
Current other anxiety disorder N (%)
Past other anxiety disorder N (%)
Past substance disorder N (%)
IDSSR M (s.d.)
STAI—Trait M (s.d.)
STAI—State M (s.d.)
PSS M (s.d.)

No Adversity/No Disorder
(n = 96)

Adversity/No Disorder
(n = 60)

No Adversity/Disorder
(n = 51)

29.60 (10.04)a
38 (39.6)
74 (77.1)a
54 (56.3)
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
6.39 (5.90)a
27.48 (7.28)a
26.56 (6.94)a
16.33 (5.67)a

31.90 (10.19)a
22 (36.7)
37 (61.7)b
24 (40.0)
15 (25.0)a
10 (16.7)a
13 (21.7)a
16 (26.7)a
10 (16.7)a
15 (25.0)
21 (35.0)
1.73 (1.16)a
—
—
—
—
—
—
—
—
—
—
—
9.29 (6.69)a
31.43 (9.79)b
27.95 (7.13)a
18.89 (6.81)b

32.08 (11.29)a
21 (41.2)
46 (90.2)a
23 (45.1)
-—
—
—
—
—
—
—
—
9 (17.6)a
18 (35.3)
4 (7.8)
4 (7.8)
0 (0.0)
2 (3.9)
2 (3.9)
1 (2.0)
4 (7.8)
2 (3.9)
27 (52.9)a
16.43 (12.87)b
38.14 (12.55)c
35.32 (12.98)b
23.88 (9.64)c

Adversity/Disorder
(n = 133)
35.95
46
108
44
68
48
50
72
45
23
30
2.62
44
43
16
20
4
11
7
5
4
11
48
21.81
39.41
34.43
23.83

(12.37)b
(34.6)
(81.2)a
(33.1)
(51.1)b
(36.1)b
(37.6)b
(54.1)b
(33.8)b
(17.3)
(22.6)
(1.51)b
(33.1)b
(32.3)
(12.0)
(15.0)
(3.0)
(8.3)
(5.3)
(3.8)
(3.0)
(8.3)
(36.1)b
(13.57)c
(11.27)c
(10.10)b
(8.47)c

P
0.00
0.81
0.00
0.35
0.00
0.01
0.03
0.00
0.02
0.26
0.13
0.00
0.04
0.70
0.41
0.20
0.21
0.30
0.71
0.54
0.15
0.30
0.04
0.00
0.00
0.00
0.00

Abbreviations: ANOVA, analysis of variance; Dep, depression; IDSSR, Inventory of Depressive Symptomatology, Self-Report; MDD, major depressive disorder;
NOS, not otherwise speciﬁed; PTSD, post-traumatic stress disorder; STAI, State-Trait Anxiety Inventory. Note: In four group analyses, P-values indicate ANOVA
signiﬁcance level. In two group analyses, P-values indicate t-test and Χ2-signiﬁcance level. Different superscripts within the same line indicate groups are
signiﬁcantly different from one another at Po0.05. Other anxiety disorders include generalized anxiety disorder, panic disorder, agoraphobia and anxiety
disorder NOS.
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Figure 1.

Group differences in methylation at individual NR3C1 CpG sites Note. tP o0.10; *Po0.05; **P o0.01.

Po 0.001), CpG 10 (F = 2.70, P = 0.046), CpG 11 (F = 2.82, P = 0.039),
CpG 12 (F = 7.35, P o 0.001) and CpG 13 (F = 4.18, P = 0.006), and a
trend-level effect at CpG 8 (F = 2.39, P = 0.069). The No Adversity/
No Disorder group had the highest levels of methylation, and this
was the only group to differ signiﬁcantly from any other group.
The two Adversity groups showed the most consistent differences
across this region, and, in addition, the No Adversity/Disorder
Translational Psychiatry (2016), 1 – 9

group also had signiﬁcantly lower levels of methylation at
CpGs 6, 9, 12 and 13.
Analysis of diagnostic categories
Participants with any lifetime depressive disorder (F = 7.54, P = 0.007,
n = 115), any lifetime anxiety disorder (F = 5.89, P = 0.017, n = 40)
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Table 2.

CpG site-speciﬁc methylation for signiﬁcant disorder and adversity types in comparison with No Adversity/No Disorder group

CpG site Depressive Disorder
(n = 115)
Mean
1
2
3
4
5
6
7
8
9
10
11
12
13

Anxiety Disorder
(n = 40)

Past Substance
Disorder (n = 75)

Emotional Abuse
(n = 83)

Emotional Neglect
(n = 88)

Physical Neglect
(n = 55)

Parental Desertion
(n = 51)

5.89*
ns
ns
ns
ns
ns
11.75***
5.08*
ns
14.05***
5.28*
5.59*
13.01***
12.47***

3.89*
ns
ns
ns
ns
ns
7.40**
ns
ns
8.25**
ns
3.15t
8.64**
7.03**

6.45*
ns
ns
ns
ns
ns
8.02**
3.59t
3.49t
11.02***
6.06*
5.76*
14.03***
7.76**

6.63*
ns
ns
ns
ns
ns
11.60***
3.38t
ns
12.35***
5.33*
4.84*
15.94***
8.07**

7.19**
ns
ns
ns
ns
ns
8.65**
4.37*
3.15t
12.71***
9.47**
6.96**
17.66***
10.33**

6.99**
ns
ns
ns
ns
ns
12.67***
ns
3.34t
8.77**
5.18*
5.79*
11.24***
5.68*

7.54**
ns
ns
ns
ns
ns
14.56***
3.44t
ns
19.56***
6.09*
6.07*
21.02***
12.48***

Abbreviation: ns, not signiﬁcant. Note: All table values represent the F statistic. tP o0.10, *Po0.05, **P o0.01, ***Po0.001.

the No Adversity/No Disorder group (n = 96) did not reach
signiﬁcance (P = 0.15, 0.17 and 0.11, respectively).

Cortisol (Log transformed nmol/L)

2.4

2.2

2

1.8
CRH

1.6
No Adversity/No Disorder
Adversity/No Disorder
No Adversity/Disorder
Adversity/Disorder

1.4

1.2

0

30

45

60

75

120

Elapsed Time (Minutes)

Figure 2. Cortisol response to dexamethasone/corticotropin-releasing hormone (Dex/CRH) test in relation to adversity/disorder
grouping. Note: the general linear model testing the effect of group
on cortisol response over time did not reach signiﬁcance (F(3,
220) = 2.08, P = 0.103).

and any past substance-use disorder (F = 3.89, P = 0.050, n = 75)
had lower levels of methylation than those in the No Adversity/No
Disorder group (n = 96) across the 13 CpG sites. Table 2 shows
results of post hoc analyses of associations of individual CpG sites
with these disorders. There was no signiﬁcant difference in mean
methylation between those with No Adversity/No Disorder and
those with lifetime MDD (P = 0.132, n = 97) or those with lifetime
PTSD (P = 0.422, n = 16).
Analysis of adversity types
Participants who experienced emotional abuse (F = 6.45, P = 0.012,
n = 83), emotional neglect (F = 6.63, P = 0.011, n = 88), physical
neglect (F = 7.19, P = 0.008, n = 55) and parental desertion (F = 6.99,
P = 0.009, n = 51) had lower levels of methylation than those in the
No Adversity/No Disorder group across the 13 CpG sites. Table 2
shows results of post hoc analyses of associations of individual
CpG sites with these adversity types. The reduced mean
methylation in those with physical abuse (n = 58), sexual abuse
(n = 63) and parental death (n = 38) in comparison with those in

Associations of the number of adversities with NR3C1 methylation
The number of adversities was negatively associated with mean
methylation across the 13 CpG sites (r = − 0.11, P = 0.046), and post
hoc analyses of individual sites showed signiﬁcant negative
associations with CpGs, 6, 7, 9, 10, 11, 12 and 13 (P-valueso 0.05).
Participants with disorders (lifetime depressive and anxiety
disorders and past substance-use disorders) had a greater number
of total adversities and were more likely to have each type of
maltreatment (Table 1). There was a signiﬁcant interaction of
the number of adversities and lifetime psychiatric disorder
(F(1, 334) = 5.84, P = 0.016), such that number of adversities was
negatively associated with mean methylation across the region in
participants with no lifetime disorder (r = − 0.19, P = 0.017), but not
in those with a lifetime disorder (r = − 0.03, not signiﬁcant). Post
hoc examination of the individual CpG sites revealed that this
effect was signiﬁcant for CpG 2 (F = 4.50, P = 0.035), CpG 3
(F = 6.92, P = 0.009), CpG 6 (F = 4.00, P = 0.046), CpG 8 (F = 5.12,
P = 0.024), CpG 10 (F = 4.30, P = 0.039), CpG 11 (F = 4.60, P = 0.033)
and CpG 12 (F = 4.22, P = 0.041). There were trend-level effects of
the interaction on methylation at CpGs 1, 9 and 13 (P = 0.085,
0.057 and 0.092, respectively). Consistent with the effect for mean
methylation across the 13 CpG sites, the number of adversities
was negatively associated with individual CpG site methylation in
those participants without psychopathology (r’s range from − 0.14
to − 0.19, P’s range from 0.02 to 0.09), but was not associated with
methylation at the individual CpG sites in participants with
lifetime psychiatric disorders (r’s range from − 0.06 to 0.07, P’s
range from 0.35 to 0.89).
Sensitivity analyses
As shown in Table 1, there were signiﬁcant differences between
the four groups in perceived stress (F = 20.13, P o0.001),
depressive symptoms (F = 44.10, P o0.001), state-related anxiety
symptoms (F = 17.27, P o0.001) and trait-related anxiety symptoms (F = 26.40, P o0.001). Mean methylation across the 13 CpG
sites was negatively associated with trait-related anxiety symptoms and with perceived stress at the trend level (r = − 0.11,
P = 0.057; r = − 0.11, P = 0.066, respectively), but not with depressive symptoms or state-related anxiety symptoms. When added to
the model assessing effects of the Adversity/Disorder grouping,
none of these variables was signiﬁcantly associated with mean
Translational Psychiatry (2016), 1 – 9

Methylation of the leukocyte GR gene promoter
AR Tyrka et al

6
Table 3.

Associations of NR3C1 methylation at individual CpG sites and cortisol concentrations in the Dex/CRH test

Post-Dex
AUC

Mean CpG 1 - 13

CpG 1

CpG 2

CpG 3

CpG 4

CpG 5

CpG 6

CpG 7

CpG 8

CpG 9

CpG 10

CpG 11

CpG 12

CpG 13

0.148*
0.117t

0.209**
0.056

0.136*
0.028

0.206**
0.083

0.106
0.026

0.147*
0.058

0.113t
0.122t

0.162*
0.114t

0.118t
0.166*

0.155*
0.098

0.098
0.095

0.122t
0.139*

0.143*
0.093

0.126t
0.099

Abbreviations: AUC, area under the curve; Dex/CRH, dexamethasone/corticotropin-releasing hormone. Note: values indicate Pearson’s Coefﬁcient; tPo 0.10,
*Po0.05, **Po 0.01.

methylation across the 13 CpG sites, and the Adversity/Disorder
grouping variable remained a signiﬁcant predictor of NR3C1
methylation.
Cortisol response to the Dex/CRH test
Cortisol response to the Dex/CRH test according to group is shown
in Figure 2. Although the No Adversity/No Disorder group had the
highest cortisol concentrations in the test, this did not reach
signiﬁcance (F(3, 220) = 2.08, P = 0.103). Similarly, effects of the
Adversity/Disorder grouping did not reach signiﬁcance for postDex cortisol (F(3, 222) = 2.48, P = 0.062) or cortisol AUC (F(3,
221) = 2.23, P = 0.086).
Associations of NR3C1 methylation and cortisol response to the
Dex/CRH test are displayed in Table 3. Mean methylation across
the 13 sites was positively associated with post-Dex cortisol
(r = 0.148, Po 0.05). Post hoc analyses of individual CpG sites
showed that post-Dex cortisol had signiﬁcant positive associations
with methylation at CpG 2, CpG 5, CpG 7, CpG 9 and CpG 12
(P o 0.05) and CpG 1 and CpG 3 (P o 0.01), and there was a trendlevel association with CpG 6, CpG 8, CpG 11 and CpG 13 (Po 0.10).
Cortisol AUC was associated with mean methylation across the 13
CpG sites at the trend level (P o 0.10), and exploratory analyses at
individual CpG sites showed signiﬁcant effects at CpG 8 and CpG
11 (P o 0.05), and at trend level for CpG 6 and 7 (P o 0.10).
DISCUSSION
In this study we found that adults with a history of childhood
adversity had reduced levels of methylation in exon 1F of the
promoter of the GR gene. In addition to lower levels of
methylation across the region, the groups with early adversity
showed lower methylation at several individual CpG sites. The
group with lifetime depressive, anxiety and substance-use
disorders who did not have a history of childhood adversity had
trend-level reductions in mean methylation across this region,
with a few of the individual CpG sites showing signiﬁcantly lower
methylation in this group. Consistent with the expectation that
lower methylation would be associated with greater GR numbers
and enhanced glucocorticoid negative feedback, lower methylation at several sites in this region was associated with lower postDex cortisol responses to the Dex/CRH test. Those with early
adversity and/or psychopathology tended to have lower cortisol
responses to the test, although this was not statistically signiﬁcant
(in the subset of the sample that participated in the Dex/CRH test).
These ﬁndings stand in contrast to prior work that has
documented higher levels of methylation of this region of
NR3C1 with early stress.27,31,35,36,38,48 However, some studies have
found reduced methylation at individual CpG sites in NR3C1 1F in
association with early stress.28,35,38 In addition, although two
studies of subjects with internalizing symptoms have shown
increased NR3C1 methylation as compared with controls,46,53
there is evidence of decreased methylation at two CpG sites
within the 1F region among patients with depression.42 Reduced
levels of methylation in this region have also been reported in
studies of patients with PTSD,44,45,54 and externalizing disorders.40
Individuals using psychotropic medication were excluded from
the present study. It is important to note that most of the prior
Translational Psychiatry (2016), 1 – 9

work on NR3C1 methylation in patients with psychiatric conditions
did not exclude patients on psychotropic medication that can
alter methylation levels.48–50 Our ﬁnding of reduced levels of
methylation could be due to a loss of methyl groups over time, or
inhibition of methylation in response to stress and trauma. In rats,
the region of NR3C1 homologous to the 1F promoter is
epigenetically regulated in response to chronic stress exposure
in adulthood.67 Thus, it is possible that some of the group
differences we observed may have occurred in response to
experiences occurring over time in adulthood; however, it is
important to note that effects of current symptoms or perceived
stress did not account for our group ﬁndings.
We believe this is the ﬁrst study to examine NR3C1 methylation
in adults with and without a history of childhood adversity and
with and without depressive, anxiety or substance-use disorders.
The groups with early adversity, with or without psychopathology,
had signiﬁcantly lower methylation across the 13 sites and at
several individual CpG sites. Participants with lifetime depressive,
anxiety or substance-use disorders but no childhood adversity had
numerically lower mean methylation across this region; however,
this contrast did not reach statistical signiﬁcance. Post hoc
examination of individual CpG sites suggested that the group
with psychopathology alone had lower methylation of some, but
not all, of the sites that were signiﬁcant for early adversity. The
group with both adversity and lifetime psychopathology tended
to show the greatest difference from controls; however, it should
be noted that this group had more adverse early experiences, and
that methylation in this group did not differ signiﬁcantly from
those with adversity but without lifetime psychopathology. The
number of adversities was associated with lower methylation
across the region and at several individual CpG sites in those
without lifetime disorders, suggesting a dose effect. Taken
together, these ﬁndings suggest that childhood adversity
inﬂuences NR3C1 methylation and may represent a risk factor
for the development of psychopathology. Psychiatric disorders
may contribute to alterations in methylation of NR3C1 to a lesser
degree, possibly via effects of these disorders on behavioral and
physiological factors involved in stress responses.
We also examined the contributions of speciﬁc types of
adversity and disorders. All adversity types were associated with
lower methylation, and adversity types that tend to be chronic,
including emotional abuse, emotional neglect, physical neglect
and parental desertion were statistically signiﬁcant. In contrast,
physical abuse, sexual abuse and parental death did not reach
statistical signiﬁcance; these forms of adversity may be less
pervasive and chronic than the other types, and children with
such experiences may also experience buffering effects of positive
emotional inﬂuences. Turning to individual disorder types, lifetime
depressive disorder, lifetime anxiety disorder and past substance
abuse showed signiﬁcant effects, whereas lifetime PTSD did not,
and lifetime MDD did not reach signiﬁcance. However, it is
important to note that lifetime MDD (n = 97) was included in the
signiﬁcant effect for the lifetime depressive disorder (N = 115)
group. The number of participants with lifetime PTSD was small
(n = 16), limiting our power to detect an effect.
In our prior preliminary work with a sample of 99 healthy adults
with no lifetime psychopathology, we found that early adversity
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was associated with greater methylation in this region of NR3C1.
Although the same technique was used to measure methylation in
both samples, methylation levels in the current sample were lower
overall in comparison with the prior sample. The previous sample
was younger, with a mean age of 27, and there may be loss of
methylation with age;68,69 however, we did control for age in the
analyses. In our prior study, effects of early adversity were seen at
CpGs 1–4, a region where methylation was particularly low in the
current sample; therefore, there may be a 'ﬂoor effect'. In the
present study, hypomethylation with adversity and psychopathology occurred in regions with overall higher levels of methylation.
With respect to cortisol responses to the Dex/CRH test, in our prior
study we found attenuated cortisol responses in association with
higher methylation at CpG 2 and in exploratory analyses of sites
CpG 5 and 7–13. We noted that this contrasted with prior work
and seemed unlikely to reﬂect a direct effect of methylationinduced decreases in GR expression. In this much larger study of
individuals with and without early adversity and with and without
certain lifetime disorders, we ﬁnd small but signiﬁcant positive
associations of post-dexamethasone cortisol with mean methylation and at several CpG sites across this region, as well as a trend
for cortisol AUC. The direction of this effect is in keeping with
ﬁndings of most, but not all, other studies,26 and with the
expectation that lower methylation would be associated with
increased gene expression and thus with enhanced HPA-axis
negative feedback and reduced cortisol responses. These results
from our study and others suggest that methylation of NR3C1 and
its relationship to HPA-axis function is complex. It is possible that
other factors such as participant age at the time of exposure to
critical stressors, unmeasured adverse experiences, chronicity or
severity of stressors, methylation of other HPA-regulatory genes or
other factors inherent to depressive, anxiety and substance-use
disorders also inﬂuenced NR3C1 methylation.26
Differential methylation of key TF-binding sites within the
promoter regions is one mechanism by which adversity could
exert inﬂuence on NR3C1 expression. The 1F region of NR3C1
contains binding sites for the nerve growth factor-inducible
protein A (NGFI-A) that increases expression of GR, an effect that
can be inhibited by methylation of these sites in both humans and
the homologous 17 region in rodents.23,38 Several,23–26,31,32,36,70
but not all27–29,33 studies have found increased methylation at the
canonical NGFI-A-binding site (CpG 3 and CpG 4 in the present
study), in humans and rodents with early adverse environmental
exposures; this may have a functional effect on HPA-axis
activity.28,31,71 Other studies have also reported a positive
association between adversity and methylation of other canonical
and non-canonical NGFI-A-binding sites within the 1F
region.29,38,53 Decreased methylation within the NGFI-A-binding
site has been documented in MDD42 and PTSD.42,45 In the present
study we did not ﬁnd an effect of the adversity/disorder grouping
on methylation at this binding site; however, the number of
adversities was negatively linked to methylation at CpG 3 in those
with no psychopathology, and there was a signiﬁcant positive
correlation between CpG 3 methylation and post-dexamethasone
cortisol.
Some evidence indicates that interference with NGFI-A binding
is not sufﬁcient to reduce GR transcription and that methylation of
other TF-binding sites across the 1F region may be involved.67
Armstrong et al.51 ran a sequence-based in silico query to identify
other possible transcription factor-binding sites within NR3C1 1F.
Numerous potential binding sites were identiﬁed, including sites
for the alcohol dehydrogenase regulator 1, speciﬁcity protein 1
and heat shock factor.51 Some of these factors, such as heat shock
factor that lies in proximity to CpG 9, are known to be involved in
immune and stress responses.72 Consistent with this, CpG 9
showed differential methylation for all adversity types and
diagnostic categories in this study. Putative binding sites for
alcohol dehydrogenase regulator 1 reside in proximity to CpGs 4,

10, 11 and 13, which showed differential methylation with many
adversity and diagnostic categories in our analyses. Putative sites
for speciﬁcity protein 1 lie in proximity to CpGs 7 and 12, units that
also showed differential methylation with several of our adversity
and diagnostic categories. Differential methylation of CpGs within
these binding sites may interfere with TF binding and regulate GR
expression in response to adversity.
However, it is important to note that, consistent with ﬁndings
from numerous research laboratories,8,31,40,42,45,47,53,73,74 levels of
NR3C1 exon 1F methylation in this study were quite low, and may
not be high enough to interfere with TF binding. Low levels of
methylation typically characterize regions of the genome that are
open to regulation by methylation.22,75,76 In contrast, high
methylation is seen in areas where CpG density is low and
transcription is not usually initiated.75 Our investigation was
limited by the lack of gene expression data, but our ﬁnding linking
lower levels of methylation at several CpG sites to lower Dex/CRH
cortisol responses is consistent with prior work45,77 and suggests
that reduced methylation could have a functional effect on
expression of GR.
This study is limited by the use of whole blood containing DNA
from multiple different cell types. It is possible that our results
were affected by differences in methylation across leukocyte types
that might co-vary with adversity and psychopathology. We
attempted to minimize such effects by excluding participants with
acute or chronic illness or pregnancy. Our use of peripheral blood
limits our ability to draw conclusions about central processes.
However, peripheral and central DNA methylation and expression
is likely to be more highly co-regulated for systems that have
widespread effects, such as the glucocorticoid and immune
systems.73,74 We did not assess lifetime externalizing disorders;
recent work suggests that externalizing disorders are associated
with a decrease in NR3C1 methylation levels;40 therefore, such a
history may contribute to the methylation patterns observed in
this study. Other limitations include the cross-sectional and
retrospective nature of the study and adversity data, the inclusion
of participants taking oral contraceptives and the lack of control
for menstrual phase in females. However, in contrast to most
studies of NR3C1 methylation in psychiatric conditions, a major
strength of this study is that we excluded individuals taking other
medications as well as individuals with acute or chronic medical
conditions. Finally, it should be noted that we did not include
examination of additional genes or markers of global methylation.
Epigenetic changes to other genes that are involved in the
response to adversity and risk for psychopathology and other
poor health outcomes78–80 should be considered in future work.
In conclusion, our ﬁndings of lower levels of methylation of the
1F promoter region of NR3C1 in relation to early stress and
psychiatric conditions that are often associated with stress
exposure suggest that these relationships are more complex than
previously understood. Future work is needed to replicate these
ﬁndings and clarify the mechanisms and sequelae of differential
methylation of NR3C1 in association with early stress and
psychopathology.
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